SNPMiner Trials (Home Page)
Report for SNP rs8192620
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Effects of Genotype on Resting State Connectivity During Methamphetamine Administration
Addiction to methamphetamine (MA) is a serious health problem in the United States. Right now, there are no medically approved treatments for MA dependence. More research is needed to understand how MA affects the brain and to eventually develop medical interventions for MA addiction. The purpose of the study is to learn more about how MA use affects the brain by investigating a receptor in the brain called trace amine-associated receptor 1 (TAAR1). The investigators are hoping to find out if individuals with certain versions of the brain receptor react differently when given MA. The TAAR1 receptor has two prevalent genetic variations due to a single nucleotide polymorphism. These are the wild type (WT) and a common variant (CV). Preliminary studies have shown that these variants produce different connectivity (resting state functional connectivity or RSFC) in the brains of individuals with MA use disorder (MUD), specifically that individuals with the CV genotype exhibit lower RSFC than WT. In this study, MA will be administered to individuals in order to: 1. Determine the influence of CV vs. WT genotype on RSFC and craving in individuals with chronic MUD. 2. Determine the effect of acute methamphetamine or placebo administration on the interaction of CV vs WT genotype on RSFC, craving, cognitive control, attention and subjective experience in MUD.
NCT03973489 Methamphetamine-dependence Behavioral: Magnetic resonance imaging (MRI) Drug: Methamphetamine Hydrochloride Tablets Drug: Placebo oral tablet
The SNP (rs8192620 on human [GRCh38.p7]
Primary Outcomes
Description: The magnitude of connectivity changes between groups during resting state will be assessed and reported using an analysis of variance (ANOVA).
Measure: Brain activation during resting state MRI Time: 1 day